Risk factors for the mortality of hemodialysis patients with COVID-19 in northern Hunan province, China
- PMID: 39819677
- PMCID: PMC11736950
- DOI: 10.1186/s12882-025-03946-2
Risk factors for the mortality of hemodialysis patients with COVID-19 in northern Hunan province, China
Abstract
Purpose: Exploring the risk factors for mortality of hemodialysis patients undergoing COVID-19 and the changes in mortality before and after the opening of the epidemic in northern Hunan province, China.
Methods: We analyzed 230 hemodialysis patients with COVID-19 in the Yiyang Central Hospital from November 01, 2022 to February 28, 2023. Demographic data, laboratory data and public diseases were collected. Cox regression analysis was used to identify risk factors and independent predictors of mortality. The receiver operating characteristic (ROC) curve was used to determine the diagnostic value of risk factors in hemodialysis COVID-19 patients.
Results: The average duration of the disease was 12.53 days. The mortality rate in our cohort was 28.70%. Independent predictors of mortality in our cohort were: age (hazard ratio [HR] 1.09; 95% confidence interval [CI], 1.05-1.14; P < 0.001), elevated procalcitonin (PCT) levels (HR 1.02; 95%CI, 1.01-1.03; P < 0.001), and higher white blood cell-neutrophil ratio (NWR) (HR 1.04; 95%CI, 1.04-1.07; P = 0.004). Areas under the ROC curve (AUC) for age, NWR, PCT, age*NWR were 0.70 (95%CI: 0.62-0.77), 0.82 (95%CI: 0.75-0.90), 0.64 (95%CI: 0.55-0.73), and 0.89 (0.85,0.94).
Conclusion: We discovered that old age, high levels of NWR and PCT might be predictors of mortality, reported the causes and prognostic predictors of mortality in hemodialysis populations with COVID-19 from northern Hunan, China.
Keywords: COVID-19; Hemodialysis; Mortality; Prognosis.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The study was approved by the Ethics Committee of Yiyang Central Hospital. As this study was not a clinical trial with intervention, informed consent was exempted by the Ethics Committee. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Figures
Similar articles
-
Association of procalcitonin levels with the progression and prognosis of hospitalized patients with COVID-19.Int J Med Sci. 2020 Sep 9;17(16):2468-2476. doi: 10.7150/ijms.48396. eCollection 2020. Int J Med Sci. 2020. PMID: 33029089 Free PMC article.
-
Impaired immune and coagulation systems may be early risk factors for COVID-19 patients: A retrospective study of 118 inpatients from Wuhan, China.Medicine (Baltimore). 2020 Aug 28;99(35):e21700. doi: 10.1097/MD.0000000000021700. Medicine (Baltimore). 2020. PMID: 32871887 Free PMC article.
-
Searching for a role of procalcitonin determination in COVID-19: a study on a selected cohort of hospitalized patients.Clin Chem Lab Med. 2020 Nov 19;59(2):433-440. doi: 10.1515/cclm-2020-1361. Clin Chem Lab Med. 2020. PMID: 33554505
-
Study on the predictive value of laboratory inflammatory markers and blood count-derived inflammatory markers for disease severity and prognosis in COVID-19 patients: a study conducted at a university-affiliated infectious disease hospital.Ann Med. 2024 Dec;56(1):2415401. doi: 10.1080/07853890.2024.2415401. Epub 2024 Oct 24. Ann Med. 2024. PMID: 39444292 Free PMC article.
-
Procalcitonin Has Good Accuracy for Prognosis of Critical Condition and Mortality in COVID-19: A Diagnostic Test Accuracy Systematic Review and Meta-analysis.Iran J Allergy Asthma Immunol. 2020 Dec 19;19(6):557-569. doi: 10.18502/ijaai.v19i6.4926. Iran J Allergy Asthma Immunol. 2020. PMID: 33463126
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical